Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment
M Janelle Cambron-Mellott1, Jaromir Mikl2, Joana E Matos1
1Kantar Health, New York, NY, USA.
Patient Preference and Adherence
|May 31, 2021
Summary
Adults with attention deficit hyperactivity disorder (ADHD) have varied preferences for stimulant treatments. Speed of onset is highly valued, while risk of rebound is least preferred, indicating personalized treatment is key.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Attention deficit hyperactivity disorder (ADHD) management necessitates integrated psychosocial and pharmacological strategies.
- Stimulant medications are a cornerstone of ADHD treatment for adults.
- Individualized treatment selection is crucial for optimizing therapeutic outcomes.
Purpose of the Study:
- To investigate adult ADHD patients' preferences for attributes of long-acting stimulant treatments.
- To identify distinct patient subgroups based on their treatment attribute preferences.
Main Methods:
- A cross-sectional online survey was administered to 200 US adults diagnosed with ADHD.
- A discrete choice experiment was employed to assess patient preferences for various treatment attributes.
- Statistical analyses identified preference patterns and patient subgroups.
Main Results:
- Adults with ADHD prioritized rapid onset of action and minimized the risk of symptom rebound.
- Three distinct preference groups emerged: side effect-sensitive (35%), rapid onset-focused (24%), and rapid onset/long duration-focused (42%).
- Significant heterogeneity exists in how patients weigh treatment benefits and risks.
Conclusions:
- Patient preferences for ADHD stimulant attributes vary considerably.
- Understanding these preferences is vital for shared decision-making between patients and physicians.
- Tailoring stimulant selection to individual patient priorities can enhance treatment efficacy and satisfaction.
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
483
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
483
01:22Alzheimer's Disease: Treatment
457
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
457
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.5K
01:28Drug Therapy
133
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
133
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
48
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
48
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
48
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
48